JPWO2021085650A1 - - Google Patents

Info

Publication number
JPWO2021085650A1
JPWO2021085650A1 JP2021553752A JP2021553752A JPWO2021085650A1 JP WO2021085650 A1 JPWO2021085650 A1 JP WO2021085650A1 JP 2021553752 A JP2021553752 A JP 2021553752A JP 2021553752 A JP2021553752 A JP 2021553752A JP WO2021085650 A1 JPWO2021085650 A1 JP WO2021085650A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021553752A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021085650A1 publication Critical patent/JPWO2021085650A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021553752A 2019-10-31 2020-11-02 Pending JPWO2021085650A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019198845 2019-10-31
PCT/JP2020/041112 WO2021085650A1 (fr) 2019-10-31 2020-11-02 Vaccin

Publications (1)

Publication Number Publication Date
JPWO2021085650A1 true JPWO2021085650A1 (fr) 2021-05-06

Family

ID=75715507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553752A Pending JPWO2021085650A1 (fr) 2019-10-31 2020-11-02

Country Status (2)

Country Link
JP (1) JPWO2021085650A1 (fr)
WO (1) WO2021085650A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008918A2 (fr) * 2005-07-08 2007-01-18 Wayne State University Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles

Also Published As

Publication number Publication date
WO2021085650A1 (fr) 2021-05-06

Similar Documents

Publication Publication Date Title
BR112021017339A2 (fr)
BR112021018450A2 (fr)
BR112021017939A2 (fr)
BR112021017892A2 (fr)
BR112021017738A2 (fr)
BR112021017782A2 (fr)
BR112021018168A2 (fr)
BR112021017728A2 (fr)
BR112021017234A2 (fr)
BR112021017355A2 (fr)
BR112021017173A2 (fr)
BR112021018102A2 (fr)
BR112021017083A2 (fr)
BR112021017637A2 (fr)
BR112021018452A2 (fr)
BR112021018250A2 (fr)
BR112021018084A2 (fr)
BR112021018093A2 (fr)
BR112021017703A2 (fr)
BR112021018484A2 (fr)
BR112021017732A2 (fr)
BR112021017949A2 (fr)
BR112021017983A2 (fr)
BR112021016205A2 (fr)
BR112021016996A2 (fr)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220318